Bavarian Nordic A/S announced a revised contract with the Public Health Agency of Canada (PHAC) to supply doses of IMVAMUNE® smallpox vaccine at a value of approximately USD 234 million in addition to USD 180 million in contract options. This extends the USD 56 million contract awarded in June 2022 to a total value of up to USD 470 million. Furthermore, a new multi-year contract has been signed with Canada's Department of National Defence (DND) at a value of USD 2 million, in addition to USD 18 million in contract options.

Through these agreements, the majority of the firm order supply will be delivered in 2023 with the option to procure additional doses annually until 2032 for a total additional value of up to USD 198 million. About the smallpox/monkeypox vaccine: MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic (marketed as IMVANEX® in Europe, JYNNEOS® in the U.S. and IMVAMUNE® in Canada) is a non-replicating smallpox vaccine developed in collaboration with the U.S. government to ensure supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines. In addition to smallpox, the U.S. Food and Drug Administration, Health Canada and the European Commission have also approved the vaccine for use against monkeypox as the only vaccine having obtained this to-date.